Wednesday, February 10, 2016

Teva's 'Plan B' morning-after pill might get greater availability

Backed by a court decision, Teva wants the FDA to approve its Plan B morning-after contraceptive pill to be available over the counter to all women. As of now, girls under age 17 need a prescription.

Teva's 'Plan B' morning-after pill might get greater availability


The Associated Press reported that the U.S. Food and Drug Administration is considering whether it's OK for young teenagers to buy emergency contraception without a prescription.

Teva Pharmaceuticals, which has operations in North Wales, is expecting a decision Wednesday regarding whether Teva's Plan B morning after pill will be available in a truly over-the-counter format.

The AP report also says the pill can prevent pregnancy if taken soon after unprotected sex. Currently, women 17 and older can buy it without a prescription if they show a pharmacist proof of age. Younger teens need a prescription. Doctors' and women's health groups have long argued that the pill is safe even for younger teens and that lifting the age restriction would increase access for everyone.

Bloomberg noted that women's health groups have favored the move, which is being considered following a 2009 court case won by Teva, but conservative groups opposed the potential change because allowing younger girls unrestricted access means they may not get needed counseling or testing for sexually transmitted diseases.

“This means that all women will have timely access to this safe backup method of contraception if they need it,” said Amy Allina, a program director at the National Women’s Health Network in Washington, told Bloomberg. “We are extremely optimistic.”

Donna Harrison of the American Association of Pro-Life Obstetricians and Gynecologists, based in Holland, Michigan, said that along with concerns about testing and counseling, U.S. officials should consider that predatory males may force minors to use the product.

“This is not a health product,” Harrison said, according to Bloomberg. “We are isolating the women who need to see doctors most.”



Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Staff Writer
Also on
letter icon Newsletter